1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBRD5648Cat. No.: HY-116830BCAS No.: 2056261-42-6Synonyms: (R)-BRD0705分式: CHNO分量: 321.42作靶點: Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 300 mg/mL (933.36 mM; Need ultra

2、sonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.1112 mL 15.5560 mL 31.1119 mL5 mM 0.6222 mL 3.1112 mL 6.2224 mL10 mM 0.3111 mL 1.5556 mL 3.1112 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?，配制前請先配制澄的儲備液，再依次添加助溶?為保證實驗結(jié)果的可靠性，體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當天使；澄的儲備液可以根據(jù)儲存條件，適當保存；

3、以下溶劑前的百分指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 7.5 mg/mL (23.33 mM); Clear solutionBIOLOGICAL ACTIVITY1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 BRD5648 (R)-BRD0705)種活性的 BRD0705 的 R 型異構(gòu)體，BRD0705種有效的，具有旁系選擇性和服活性的 GSK3 抑制劑，IC50 為 66 nM，Kd 為 4.8

4、M。BRD0705 與 GSK3 (IC50 為 515 nM) 相，對GSK3 的選擇性更 (8 倍)。BRD0705 可于急性髓細胞性病。體外研究 BRD5648, the inactive enantiomer of BRD0705, does not induce changes in enzyme phosphorylation or total-catenin protein stabilization 1.REFERENCES1. Wagner FF, et al. Exploiting an Asp-Glu switch in glycogen synthase kinase

5、3 to design paralog-selective inhibitors for use in acutemyeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460.2. Wagner FF, et al. Exploiting an Asp-Glu switch in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acutemyeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 0